In the treatment of diabetes with basal insulin
Start your patient’s journey with Tresiba®
Tresiba® is a long-acting basal insulin indicated to improve glycemic control in patients with diabetes.1
See the Tresiba® U-100 data on the risk of major adverse cardiovascular events (MACE) and rates and incidence of severe hypoglycemia vs insulin glargine U-100 for patients with T2D and ASCVD.1,a
aSevere hypoglycemia was defined as an episode requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions and during which plasma glucose concentration may not have been available, but where neurological recovery following the return of plasma glucose to normal was considered sufficient evidence that the event was induced by a low plasma glucose concentration.1
ASCVD=atherosclerotic cardiovascular disease; T2D=type 2 diabetes.